Guggenheim Capital LLC raised its stake in shares of Medtronic plc. (NYSE:MDT) by 8.0% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 894,952 shares of the medical technology company’s stock after purchasing an additional 66,060 shares during the quarter. Guggenheim Capital LLC owned about 0.07% of Medtronic worth $72,266,000 at the end of the most recent reporting period.
A number of other institutional investors also recently modified their holdings of MDT. Quadrant Capital Group LLC increased its stake in Medtronic by 21.5% during the 2nd quarter. Quadrant Capital Group LLC now owns 1,639 shares of the medical technology company’s stock valued at $114,000 after purchasing an additional 290 shares in the last quarter. Blue Chip Partners Inc. acquired a new stake in shares of Medtronic in the third quarter worth $118,000. Barrett Asset Management LLC increased its stake in shares of Medtronic by 856.0% in the fourth quarter. Barrett Asset Management LLC now owns 1,826 shares of the medical technology company’s stock worth $147,000 after acquiring an additional 1,635 shares during the period. Westwood Holdings Group Inc. acquired a new stake in shares of Medtronic in the second quarter worth $151,000. Finally, SevenBridge Financial Group LLC increased its stake in shares of Medtronic by 76.2% in the third quarter. SevenBridge Financial Group LLC now owns 2,197 shares of the medical technology company’s stock worth $171,000 after acquiring an additional 950 shares during the period. Institutional investors and hedge funds own 80.79% of the company’s stock.
Medtronic plc. (NYSE MDT) opened at $83.15 on Monday. Medtronic plc. has a 52 week low of $76.51 and a 52 week high of $89.72. The firm has a market cap of $112,699.27, a PE ratio of 17.73, a PEG ratio of 2.36 and a beta of 0.97. The company has a debt-to-equity ratio of 0.51, a current ratio of 2.43 and a quick ratio of 2.09.
A number of analysts have recently weighed in on MDT shares. SunTrust Banks set a $92.00 price objective on shares of Medtronic and gave the stock a “buy” rating in a research note on Sunday, November 19th. Stifel Nicolaus increased their price objective on shares of Medtronic from $83.00 to $85.00 and gave the stock a “hold” rating in a research note on Wednesday, November 22nd. Oppenheimer reiterated a “buy” rating and issued a $94.00 price objective on shares of Medtronic in a research note on Wednesday, November 22nd. Northland Securities restated a “hold” rating and set a $80.00 price target on shares of Medtronic in a research report on Wednesday, November 22nd. Finally, Zacks Investment Research upgraded shares of Medtronic from a “sell” rating to a “hold” rating in a research report on Thursday, November 23rd. One analyst has rated the stock with a sell rating, eight have assigned a hold rating and sixteen have assigned a buy rating to the company. Medtronic has an average rating of “Buy” and an average target price of $91.50.
In other Medtronic news, EVP Bryan C. Hanson sold 16,000 shares of Medtronic stock in a transaction dated Friday, December 15th. The shares were sold at an average price of $82.82, for a total transaction of $1,325,120.00. Following the completion of the sale, the executive vice president now directly owns 88,818 shares in the company, valued at $7,355,906.76. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, VP Richard Kuntz sold 78,526 shares of Medtronic stock in a transaction dated Tuesday, January 9th. The shares were sold at an average price of $86.21, for a total transaction of $6,769,726.46. Following the sale, the vice president now owns 149,761 shares of the company’s stock, valued at $12,910,895.81. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 145,163 shares of company stock valued at $12,232,045. 0.31% of the stock is owned by company insiders.
COPYRIGHT VIOLATION NOTICE: “Guggenheim Capital LLC Has $72.27 Million Position in Medtronic plc. (MDT)” was first reported by American Banking News and is the property of of American Banking News. If you are accessing this piece of content on another domain, it was stolen and republished in violation of international copyright & trademark legislation. The original version of this piece of content can be accessed at https://www.americanbankingnews.com/2018/03/12/guggenheim-capital-llc-has-72-27-million-position-in-medtronic-plc-mdt.html.
Medtronic Public Limited Company (Medtronic) is a medical technology and services company. The Company develops, manufactures and markets its medical devices and technologies to hospitals, physicians, clinicians and patients in approximately 160 countries. The Company operates in four segments: Cardiac and Vascular Group, Minimally Invasive Technologies Group, Restorative Therapies Group and Diabetes Group.
Receive News & Ratings for Medtronic Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medtronic and related companies with MarketBeat.com's FREE daily email newsletter.